Updated on 7 April 2015
Sihuan pipeline includes candidates for cardiovascular, metabolic and infectious diseases, oncology and urology
Singapore: Sihuan Pharmaceuticals recently announced that its subsidiary Shandong Xuanzhu has partnered with Covance, a contract research unit of Laboratory Corp of America Holdings to develop Sihuan's pipeline candidates
Mr Honggang Bi, corporate VP and general manager, Covance China, said, "This agreement is the first of its kind signed with a partner in the Asia Pacific region, and Covance looks forward to collaborating with Sihuan Pharmaceutical in its efforts to potentially bring global filing strategies to realization."
Sihuan said in a statement that Covance will provide clinical and research services for drug development. Dr Frank Wu, chief scientific officer of Sihuan Pharmaceutical, commented, "The partnership is another milestone for our international collaboration and R&D team and will enable us to accelerate the development of our pipeline, in turn helping to bring treatments to multiple markets faster."